Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Has osteoarthritis of the knee and primary source of pain is knee~* Females must not be pregnant or nursing and must agree to use birth control throughout the study~* Is willing to limit alcohol and caffeine intake~* Is willing to abstain from smoking during study visits~* Must be able to walk on a treadmill at a pace of at least 1 mile/hour~Exclusion Criteria:~* Has a medical/arthritic disease that would interfere with evaluation~* Is unable to take naproxen or Ultracet~* Has congestive heart failure or angina~* Has a history of stroke~* Has a history of uncontrolled high blood pressure~* Has a history of cancer~* Regularly uses a walker or cane

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo, Naproxen, Ultracet (Type: EXPERIMENTAL): Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Naproxen, Ultracet, Placebo (Type: EXPERIMENTAL): Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Ultracet, Placebo, Naproxen (Type: EXPERIMENTAL): Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Placebo, Ultracet, Naproxen (Type: EXPERIMENTAL): Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Naproxen, Placebo, Ultracet (Type: EXPERIMENTAL): Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Ultracet, Naproxen, Placebo (Type: EXPERIMENTAL): Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.

Based on this trial design, predict the completion outcome and termination type (if applicable).